Dr. Lal PathLabs Limited (NSEI:LALPATHLAB) agreed to acquire Shahbazkers Diagnostic Centre Private Limited for INR 200 million on April 30, 2026. A cash consideration of INR 200 million will be paid by Dr. Lal PathLabs Limited. As part of consideration, INR 200 million is paid towards common equity of Shahbazkers Diagnostic Centre Private Limited.
For the period ending March 31, 2026, Shahbazkers Diagnostic Centre Private Limited reported total revenue of INR 61.1 million.
The transaction is subject to approval of offer by Dr. Lal PathLabs Limited board. The deal has been approved by the board. The transaction will be completed by May 31, 2026.
Dr. Lal PathLabs Limited is an India-based provider of diagnostic and related healthcare tests and services. The Company is engaged primarily in the business of running laboratories for carrying out pathological investigations in various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations. It offers a range of tests, including Pregnancy Test, Full Body Checkups, Covid 19 Test, Heart Test, Kidney Test, Liver Test, Cholesterol Test, Hepatitis B Test, Kidney Function Test, Sugar Test, Thyroid Test, Typhoid Test, Uric Acid Test, Vitamin B12 Test and vitamin D Test. It has approximately 298 clinical laboratories (including National Reference Lab at Delhi, Regional Reference Lab in Kolkata, Bangalore and Mumbai), 6,607 patient service centers, and 12,365 pick-up points (PUPs). Its customers include individual patients, hospitals, and corporate customers.
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
